Welcome to LookChem.com Sign In|Join Free
  • or
1H-Benzimidazol-5-amine, 1-[6-[[(1S)-1-phenylethyl]amino]pyrazinyl]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

629669-63-2

Post Buying Request

629669-63-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

629669-63-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 629669-63-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,9,6,6 and 9 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 629669-63:
(8*6)+(7*2)+(6*9)+(5*6)+(4*6)+(3*9)+(2*6)+(1*3)=212
212 % 10 = 2
So 629669-63-2 is a valid CAS Registry Number.

629669-63-2Downstream Products

629669-63-2Relevant academic research and scientific papers

AZOLE-BASED KINASE INHIBITORS

-

Page/Page column 32-33, (2008/06/13)

A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating kinase-associated disease states using the compound of formula (I) is also desc

SELECTIVE KINASE INHIBITORS

-

Page/Page column 35, (2010/02/12)

A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4 are optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I).

KINASE INHIBITORS

-

Page 43-44, (2008/06/13)

A compound of the general formula (I) or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula (I) is also de

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 629669-63-2